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SUMMARY Early electron microscopy studies revealed the elaborate cellular fea-
tures that deﬁne the unique adaptations of apicomplexan parasites. Among these
were bulbous rhoptry (ROP) organelles and small, dense granules (GRAs), both of
which are secreted during invasion of host cells. These early morphological studies
were followed by the exploration of the cellular contents of these secretory organ-
elles, revealing them to be comprised of highly divergent protein families with few
conserved domains or predicted functions. In parallel, studies on host-pathogen in-
teractions identiﬁed many host signaling pathways that were mysteriously altered by
infection. It was only with the advent of forward and reverse genetic strategies that
the connections between individual parasite effectors and the speciﬁc host path-
ways that they targeted ﬁnally became clear. The current repertoire of parasite effec-
tors includes ROP kinases and pseudokinases that are secreted during invasion and
that block host immune pathways. Similarly, many secretory GRA proteins alter host
gene expression by activating host transcription factors, through modiﬁcation of
chromatin, or by inducing small noncoding RNAs. These effectors highlight novel
mechanisms by which T. gondii has learned to harness host signaling to favor intra-
cellular survival and will guide future studies designed to uncover the additional
complexity of this intricate host-pathogen interaction.
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INTRODUCTION
Toxoplasma gondii is a widespread parasite that infects many species of animals,including mammals, marsupials, and birds (1). A member of the phylum Apicom-
plexa, Toxoplasma gondii belongs to a diverse assemblage of organisms originally
estimated to comprise5,000 species (2), although recent estimates based on genomic
bar coding suggest much greater diversity (3). The majority of apicomplexans are
obligate intracellular parasites, while others only partially enter their host cell to reside
in an “epicellular” state (4). Apicomplexans infect many different hosts, including
invertebrates (i.e., insects, worms, and mollusks), where gregarines predominate (http://
tolweb.org/Gregarina/124806), as well as both cold-blooded and warm-blooded verte-
brates (4). Intracellular and epicellular lifestyles are thought to have arisen multiple
times during evolution of apicomplexans (4, 5). Apicomplexans are uniﬁed by structural
similarities at the apical end, including the conoid that organizes the cytoskeleton and
several groups of secretory organelles (6). Comparison of apicomplexans to their closest
sister taxa, the free-living photosynthetic chromerids and predatory colpodellids, re-
veals many common adaptations, while apicomplexan-speciﬁc features are limited to a
few conserved secretory proteins found in apical organelles called rhoptries and the
unique class XIV myosin and associated components of the glideosome (7). Analyses of
more than 60 T. gondii genomes in comparison with closely related parasites expand on
this theme by showing that the ampliﬁcation of polymorphic secretory proteins is
associated with the diversiﬁcation of apicomplexans within their respective vertebrate
hosts (8).
Apicomplexans are best studied where they cause disease in warm-blooded hosts,
including domestic animals and humans. Notable groups that frequently cause serious
disease in humans include Plasmodium spp., responsible for malaria (9); Cryptospo-
ridium spp., an agent of diarrheal disease (10); and T. gondii, which causes toxoplas-
mosis (11, 12). Unlike some groups of apicomplexans (e.g., Sarcocystis spp.) in which
there are many distinct species, each infecting a discrete number of hosts (13), T. gondii
is uniﬁed as a single species that infects many species of animals from diverse
geographic regions (1). As described further below, T. gondii has a relatively young
population structure, and isolates collected from diverse hosts around the world
comprise a small number of clades of closely related strains (14, 15).
Toxoplasma gondii belongs to the tissue cyst-forming branch of the enteric coccid-
ians, which contains important animal parasites such as Eimeria spp., which cause
severe economic losses in agricultural animals (16). In contrast to the direct oral-fecal
route of spread of enteric coccidians, T. gondii is transmitted by an alternating two-host
life cycle, termed a heteroxenous cycle, relying on a deﬁnitive host for sexual trans-
mission while undergoing asexual transmission in its alternative host. Different species
of cats serve as deﬁnitive hosts for T. gondii (17). Sexual development takes place in
enterocytes of the gut, resulting in the shedding of oocysts that contaminate the
environment, whereupon they undergo meiosis in a process called sporulation (18).
Oocysts are infectious to many animals, including a variety of rodents (19). During initial
infection in the intermediate host, the parasite replicates in a variety of host cell types
as tachyzoites, which expand dramatically in numbers and spread to many tissues in
the body (20). Following a potent immune response, the parasite differentiates to a
slow-growing bradyzoite, which remains semidormant within tissue cysts that reside in
long-lived cells, including neurons and skeletal muscle cells (21). Bradyzoites divide
slowly and asynchronously (22), consistent with the fact that tissue cysts grow over
time, and cysts are thought to undergo multiple rounds of growth, rupture, and
reinfection to sustain chronic infection (23). Ingestion of tissue cysts by the deﬁnitive
host completes the cycle, giving rise to oocyst shedding (24). Although the life cycle of
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T. gondii is remarkably ﬂexible, transmission between hosts is most efﬁcient when it
follows the natural life cycle: oocysts are highly infectious for intermediate hosts such
as rodents (20) and agricultural animals (25), and while they can also infect cats, the
prepatent period before oocyst shedding is much longer (26). Bradyzoites found in
tissue cysts can infect other rodents when orally ingested albeit much less efﬁciently
than the deﬁnitive cat host (24).
The life cycle of a close relative of T. gondii, Hammondia hammondi, is an example
of a very restrictive, obligatory heteroxenous cycle (27). Hammondia hammondi natu-
rally infects rodents as intermediate hosts and undergoes sexual development and
oocyst formation in cats, although it does not readily propagate in vitro and is not
transmissible between intermediate hosts (28). In contrast to this restrictive cycle, T.
gondii exhibits ﬂexibility at several key steps in its life cycle that contributes to its
successful expansion into many other hosts. First, the differentiation of tachyzoites into
bradyzoites is reversible in T. gondii, allowing the reemergence of chronic infections in
immunocompromised hosts (29). This trait allows the reisolation of T. gondii from
chronic infections by inoculating tissue homogenates onto host cells cultured in vitro
and subsequent cultivation of tachyzoites (30), making T. gondii a model for cellular and
molecular studies (see below). Second, when tissue cysts of T. gondii are ingested by
another intermediate host, they are infectious (31). Oral transmission may facilitate
spread by asexual means through carnivorous or omnivorous feeding by hosts, by-
passing the requirement for a deﬁnitive host. Strict herbivores must still be infected via
oocysts shed from cats, but once infected, they can serve as intermediate hosts for
asexual transmission through the food chain without the need for sexual development
in cats. Although related parasites such as Neospora caninum are not transmitted
between successive intermediate hosts via omnivorous or carnivorous feeding, they
can be vertically transmitted (32), a trait shared by T. gondii in mice (33) and domestic
animals such as sheep (34). The ﬂexible nature of the T. gondii life cycle may be
responsible for its widespread success as a parasite of so many diverse types of animals.
Transmission to Humans and Opportunistic Disease
Humans are accidental hosts for T. gondii and play little role in its natural life cycle.
Oocysts are highly infectious when orally ingested (25, 35), and they remain infectious
in the environment for extended time periods, as they are resistant to many condi-
tions (36–39), including chlorine sterilization procedures used on many domestic water
supplies (40). Humans can become infected by ingesting contaminated water that
contains oocysts (41), and there have been a number of documented outbreaks of
toxoplasmosis due to contamination of water supplies in British Columbia (42) and in
different regions of Brazil (43, 44). In addition to waterborne outbreaks, oocyst infec-
tions have been responsible for aerosol exposures (45) and can cause infection by
contamination of garden vegetables (46). Humans can also become infected by eating
tissue cysts found in undercooked meat of infected animals (47). Finally, vertical
transmission can result in congenital infection when a mother is newly infected during
pregnancy (48). In all of these manifestations, humans act as an intermediate host,
where the initial infection is propagated by the dissemination of tachyzoites that then
convert to semidormant bradyzoites in long-lived tissue cysts. Globally, the serological
prevalence of toxoplasmosis, largely reﬂecting subclinical chronic infections, is highly
variable, ranging from 10 to 15% in the United States to 60% in South and Central
America, parts of the Mediterranean, Europe, and Southeast Asia (49). Overall, 25% of
the world’s human population may be chronically infected with T. gondii.
In healthy adults, toxoplasmosis produces a relatively mild infection, with elevated
fever, enlarged lymph nodes, and muscle weakness (12). Normally, acute infection
resolves rapidly, leaving the individual with a chronic, subclinical infection (12). More
severe outcomes can occur with congenital infections, where, depending on the timing
of infection, the developing fetus can experience symptoms that range from severe
(usually due to infection in the ﬁrst trimester) to mild (more common when infection
occurs later during pregnancy) (48). Severe forms of congenital toxoplasmosis can
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result in hydrocephaly, microcephaly, intracranial calciﬁcation, and even loss of life (50).
Milder infections may result in few symptoms at birth (51) but can be responsible for
ocular toxoplasmosis later in life (52). Although ocular toxoplasmosis in North America
and Europe seems to be due largely to a recurrence of congenital infection, a very
different situation occurs in South America (53). In regions of southern Brazil, recurrent
and severe ocular toxoplasmosis cases have been documented in healthy adults due to
newly acquired infection (54). These episodes are associated with signiﬁcant ocular
inﬂammation, which requires treatment with corticosteroids in addition to antibiotic
therapy to reduce the risk of recurrence (55). Whether the difference in disease severity
is due to underlying differences in parasite strains (56, 57) (see below) or exposure
burden (55, 58) is unclear, but it serves as a reminder that not all T. gondii infections
in healthy adults are benign. Importantly, ocular toxoplasmosis patients in Europe
show high levels of interleukin-17 (IL-17) and interferon gamma (IFN-), while the levels
of these cytokines are much lower, with associated higher parasite loads, in South
American patients (59). In immunocompromised adults, severe infections typically
result from a reactivation of chronic infection, as seen in AIDS, organ transplant, or
chemotherapy patients (60). These severe outcomes are all consistent with a lack of
sustained immunity and the ability of the parasite to reemerge from tissue cysts and
convert back to rapidly growing tachyzoites, which leads to tissue damage. As such,
toxoplasmosis was considered a deﬁning opportunistic infection of the AIDS epidemic
(61). The introduction of highly active antiretroviral therapy (HAART) led to a drop in the
incidence of cases of reactivated toxoplasmosis (62). However, this is still a problem in
may regions due to a lack of available antiviral therapy or inadequate enrollment (63).
The problem of chronic burden persists in the population, as available therapies,
primarily pyrimethamine combined with sulfadiazine, do not eradicate the semidor-
mant bradyzoites (64). Chronic infections in humans have also been associated with an
elevated risk of psychiatric illnesses, including schizophrenia (65). Although the cau-
sality of this association has not been established, it is nonetheless worthy of further
study.
Genetic Diversity and Population Structure
Early studies of genetic diversity based on restriction fragment length polymor-
phisms (RFLPs) (66) or isoenzyme markers (67) revealed differences in T. gondii strains,
which are otherwise highly similar. These molecular typing studies also uncovered a
striking pattern of clonality among North American strains (68), which were remarkably
similar to those found in Europe (69, 70). Sampling from animal and human infections
revealed three strongly clonal genotypes that were closely related to each other (71).
Type 2 strains are most commonly associated with human infections in Europe in both
cases of congenital infection (70) and immunocompromised patients (72–74), and this
pattern is also seen in North America (71). Type 1 strains are relatively rare, although
they are distinguished by their high level of acute virulence in the mouse model (68,
71), and they show elevated frequencies in some groups of immunocompromised
patients (75). Finally, type 3 strains are relatively common in domestic and wild animals
in North America and yet are rarely found in human infection (71, 76).
The distribution of single nucleotide polymorphisms (SNPs), which were revealed by
sequencing of large numbers of cDNAs from the three clonal lineages (77), suggested
a recent common inheritance of long haploblocks across the genome (78). This pattern
is most easily explained by just a few genetic crosses that occurred in the wild between
highly similar parental strains (78). The frequency of SNPs in selectively neutral loci
(introns of housekeeping genes) was used to extrapolate the last common ancestor of
the three strain types to within 10,000 years (31). This estimate is remarkably short
considering the relatively long time span that apicomplexan parasites have been
evolving within their vertebrate hosts, estimated at 400 million years (79). The recent
ancestry of clonal T. gondii strains roughly coincides with the domestication of animals
(80), the adoption of cats as pets (81), and the intrusion of house mice as pests (82).
Hence, it appears that the convergence of deﬁnitive and intermediate hosts brought
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together favorable conditions for transmission and provided opportunities for zoonotic
infection of humans.
A number of animal and human pathogens show evidence of a loss of genetic
diversity coincident with the rise of agriculture, and this pattern may reﬂect the lower
genetic diversity of domesticated animals, which in turns selected for particular patho-
gen genotypes that were well suited in this niche (80). Why just three dominant
genotypes of T. gondii emerged in North America and Europe after the recent genetic
bottleneck is unclear, although it suggests that these genotypes are endowed with
some selective advantage. One feature that the clonal lineages share is the common
inheritance of similar forms of chromosome 1a, which has been linked to greater
transmission in domestic cats (83–86). Additionally, the ﬂexibility of the life cycle
mentioned above allows T. gondii to bypass cats when transmitted by omnivorous or
carnivorous feeding, thus potentially reinforcing this clonal population pattern. The
ability of T. gondii to pass vertically, which occurs across repeated generations in
rodents, may also contribute to asexual transmission in the wild (34). In addition to
these original three clonal genotypes, more recent studies documented the existence
of another clonal lineage in North America (87). Interestingly, strains of this fourth type
are most often found in wild animals, and they show evidence of recent genetic
exchange with type 2 strains (87). Together with their distribution in wild animals, this
suggests that this type may represent the ancestral North American lineage prior to the
emergence of the predominant clonal types.
In comparison to strains in North America and Europe, strains of T. gondii in South
America are much more genetically diverse, lack evidence of a clonal population
structure, and show greater evidence of genetic recombination (88, 89). When South
American isolates were ﬁrst genotyped by using RFLP markers developed from north-
ern strains, they appeared similar to type 1 strains or as hybrid strains (90, 91), owing
to the fact that they share some ancestral SNPs with the northern lineages (85). Deeper
analysis of the patterns of SNP inheritance from sequenced genomic regions revealed
that South American strains comprise distinct lineages that are not found in the north
(85). Shared nucleotide patterns establish a common ancestry of 1 million to 2 million
years, while much more recently derived regional patterns deﬁne groups that have
evolved in the north versus those that are restricted to the south (85). Analysis of the
population structure revealed 6 major clades containing 16 haplogroups of T. gondii
(15). These haplogroups show distinct geographical patterns, with some predominating
in North America and Europe, others being unique to South America or Asia, and at
least one showing a broad distribution globally (15). Network and population structure
analyses of the relationships among these strains suggest sporadic gene ﬂow between
them at different times in the recent past (15), a conclusion supported by data from
genome-wide SNP studies using transcriptome sequencing (RNA-Seq) (92) and whole-
genome sequencing of more than 60 diverse lineages (8). These broader patterns are
supported by speciﬁc examples of recombination in the wild generating hybrid strains
(87, 93). The potential for the spread of pathogenicity genes via recombination is an
important consideration in South America, where some genotypes have been associ-
ated with recurrent ocular disease (56, 57) or severe outcomes and even death in
healthy adults (94–96).
Collectively, these studies indicate that the current population structure of T. gondii
is derived from mosaic patterns of inheritance of blocks of conserved regions of the
genome (8). Although these studies have enriched our view of the population structure
of T. gondii, many regions of the world are still inadequately sampled (i.e., Africa, Asia,
and Southeast Asia), suggesting that greater diversity will likely be uncovered by future
studies. Importantly, next-generation (NexGen) sequencing studies have revealed that
the genome of T. gondii is distinguished from its close relatives by the ampliﬁcation of
gene families that encode surface and secretory protein families of pathogenesis
determinants (8). The pattern of inheritance of these secretory protein gene families,
which occurs in conserved blocks that deﬁne the population structure, suggests that
they impart important biological attributes to the major lineages. As described further
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below, many of these secretory proteins play speciﬁc roles pathogenesis, while the
function of others remains to be deﬁned.
HOST-PATHOGEN INTERACTIONS
Invasion and Intracellular Survival
Toxoplasma gondii is an obligate intracellular parasite, and host cell entry is para-
mount to survival. The intracellular phase of the life cycle is followed by active egress
from the host cell and then rapid reentry, as the parasite does not divide when it is
extracellular (97). The zoites of most apicomplexans show marked apical specialization,
with the formation of a microtubule-organizing center that organizes the apical end (6).
The apical end also contains a set of secretory organelles termed micronemes (98) and
rhoptries (99), which comprise different families of regulated secretory proteins. This
apical specialization gives the zoite an elongated shape that imparts physical rigidity for
supporting substrate-dependent motility.
Apicomplexan zoites display substrate-dependent gliding motility that relies on an
actin-myosin motor complex located beneath the plasma membrane, which translo-
cates adhesive microneme proteins from the apical end toward the posterior end of the
cell, similar to a conveyor belt (100). Although the biological details have been worked
out primarily for T. gondii, a very similar process drives sporozoite and merozoite
invasion in Plasmodium (101). Motility is dependent on ﬁlamentous actin assembly in
the parasite (102) as well as MyoA, a class XIV myosin located in the inner membrane
complex (103). MyoA is associated with light chains involved in regulation as well as a
complex of proteins called the glideosome that helps anchor the motor in the inner
membrane complex (104), a system of ﬂattened membranes beneath the plasma
membrane (6). The interaction between the cytoplasmic tails of adhesins and the
actin cytoskeleton is mediated by a novel connector containing a pleckstrin homology
domain and a series of armadillo repeats (105). Although the parasite actin-myosin
cytoskeleton is required for entry, and likely provides the majority of force generation,
other studies have emphasized a role for host actin remodeling during invasion (106).
Many of the parasite motor complex proteins are essential for efﬁcient cell entry, as
shown by the dramatic loss-of-function phenotypes when genes encoding these
proteins are disrupted. However, it has also been argued that there may be alternative
pathways for entry, as these mutants show some residual, albeit limited, ability to enter
cells (107, 108). In some cases, the apparent dispensability of genes previously thought
to be essential was due to functional redundancy (109) or due to the functional ability
of low levels of protein that remain after gene deletion (110). Collectively, these studies
support a model where the actin-myosin-based motor complex is of primary impor-
tance for efﬁcient cell entry by T. gondii and related apicomplexans.
Motility and host cell invasion by apicomplexans are tightly coupled to protein
secretion. The secretory system is streamlined and specialized for polarized anterior
secretion (111). The endoplasmic reticulum (ER) is continuous with the nuclear envelop,
and budding from the anterior region of the nucleus directs vesicles to the single-
stacked Golgi apparatus (112). From here, secretory proteins are sorted into speciﬁc
organelles prior to discharge. In addition to the anteriorly localized rhoptries and
micronemes, which have distinct forward-directed sorting signals, a third secretory
compartment, called the dense granule (GRA), is dispersed though the cytosol and
provides a default pathway for export (111). The endocytic pathway of apicomplexans
is highly devolved and serves functions in protein processing for the export of mi-
croneme and rhoptry proteins rather than canonical endocytic processes (111). The
timing of expression may also be important for sorting, as the genes encoding proteins
destined for each compartment are coordinately regulated during the cell cycle (113).
Overall, this system provides streamlined processes for the synthesis and export of
proteins that are destined for distinct secretory organelles.
During host cell invasion by T. gondii, regulated secretion from three different
compartments releases the contents of micronemes, rhoptries, and dense granules
(Fig. 1) (114). Initially, micronemes secrete their contents from the apical tip upon
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contact with host cells (115), in a process that is regulated by intracellular calcium (116).
Micronemes contain a number of proteins that contain adhesive domains involved in
recognizing glycoconjugates on the host cell surface (98). Second, rhoptries secrete
proteins from the neck region, so-called RON proteins, which insert into the host
membrane to form an anchoring point for the moving junction (117, 118). The contents
of the rhoptry (ROP) bulbs are also secreted into the host cell at a very early step in
invasion, in some cases releasing proteins directly into the host cytosol as well as the
lumen of the parasitophorous vacuole (PV) (119) (Fig. 1). Although the signiﬁcance of
FIG 1 Rhoptry effectors that target host pathways. Following attachment to the host cell, rhoptry (ROP)
effector proteins are released into the host cell cytosol prior to the entry of the parasite into the
parasitophorous vacuole (PV). ROP proteins are found in the cytosol, trafﬁc to the host nucleus, and also
decorate the surface of the vacuole. The secreted kinase ROP18 is assembled on the PV membrane,
where it forms complexes with another kinase, ROP17, and the pseudokinase ROP5. By the phosphor-
ylation of IRG monomers/dimers (ROP18) and polymers (ROP17), these kinases prevent the accumulation
of IRGs on the PV membrane. The pseudokinase ROP5 binds Irga6 directly and enhances the kinase
activity of ROP18. The ROP5/ROP18/ROP17 complex also contains the transmembrane protein GRA7,
originating from a parasite organelle named the dense granule. GRA7 can also bind directly to IRG
polymers, and it accelerates their turnover. ROP18 has also been shown to phosphorylate the transcrip-
tion factor ATF6, marking it for proteosomal degradation. Another secretory rhoptry kinase, ROP16,
activates the transcription factors STAT3 and STAT6 by direct phosphorylation, thus altering host
transcription.
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the release of ROP proteins into the host cytosol was not determined until much later,
it was originally suggested that this was a simple way to deliver proteins to the external
surface of the PV membrane (PVM) (120). Rhoptry proteins can also be secreted into
cells by a noninvading parasite, and hence, the delivery of effectors may alter host cell
function even in the absence of invasion (121). The ﬁnal wave of secretion occurs with
the release of dense granule proteins, many of which occupy the lumen of the vacuole
and decorate an elaborate array for membranous tubules called the intravacuolar
network (122) (Fig. 1). Several GRA proteins are also anchored in the PV membrane and
extend at least partly into the host cytosol, where they may interact with host proteins
(123–125). GRA proteins also form part of the cyst wall that surrounds bradyzoites (126,
127), and many GRA proteins play important roles at this stage of development despite
being dispensable during in vitro growth as tachyzoites (128). Recently, is was sug-
gested that there may be more than one population of dense granules based on the
fact that GRA proteins that occupy the lumen or PV membrane are released in a bolus
early in invasion, while those that trafﬁc outside the PV may be released more slowly
over time (129).
During invasion, the PV forms by invagination of host cells, as shown by electro-
physiology studies (130) as well as tracers for plasma membrane lipids (131). Despite
being formed from the host plasma membrane, the process of forming the PV is
fundamentally different from phagocytosis, as it occurs with minimal rearrangement of
the host cytoskeleton and independently of Tyr phosphorylation that normally accom-
panies phagocytic uptake (132). Many host plasma membrane proteins are excluded
from the vacuole during entry, and this exclusion is based on physical constraints and
lipid partitioning (131, 133). These ﬁnding suggest that the moving junction may form
a physical barrier for sieving proteins, and this in turn may affect the fate of the vacuole.
The T. gondii PV is nonfusogenic with host lysosomes and endosomes (134), and it
maintains a neutral pH (135). Excluded from contact with the host endomembrane and
cytosol, the parasite remains conﬁned within the PV. The parasite likely acquires
nutrients by making the vacuole membrane permeable to small metabolites (136).
Innate Immunity in Mice
Laboratory mice have been used for studying infection caused by T. gondii based on
the fact that rodents are a natural host and thus a reasonable model for studying
immune responses and pathogenesis. During initial infection of mice, the parasite
rapidly disseminates from the site of inoculation and reaches many tissues in the body
(20, 137). Interaction with innate immune cells triggers the production of IL-12 by CD8
dendritic cells (DCs) (138, 139), plasmacytoid DCs (140, 141), macrophages (142), and
neutrophils (143). One of the major pathways for trigging IL-12 is the detection of
proﬁlin, an actin binding protein, by Toll-like receptor 11 (TLR11) and TLR12 (144, 145).
This pathway is highly important for the control of infection, as shown by the suscep-
tibility of MyD88/ mice (146), which lack the major adaptor for TLR signaling. IL-12
induces the production of IFN-, initially from natural killer (NK) cells (147, 148) and
later from CD4 (149) and CD8 (150) T cells. The IL-12–IFN- axis is critical for controlling
infection, as shown by the enhanced susceptibility of mice lacking IFN- due to
antibody neutralization (151) or genetic ablation of IFN- (151), IFN- receptors (152),
or IL-12 p40 (153). IFN- signaling proceeds through STAT1 phosphorylation and
translocation to the nucleus to induce a set of interferon-stimulated genes (ISGs) (154,
155). Not surprisingly, STAT1 is also essential for the control of infection in mice (156,
157). However, when infection precedes the activation signal, T. gondii is able to block
STAT1 signaling, leading to the downregulation of inducible nitric oxide synthase
(iNOS) (158) and major histocompatibility complex class II (MHC-II) (159), among other
ISGs (160). The mechanism of this block is described further below.
A number of other innate pathways are important for the control of chronic
infection but are not essential during acute infection, including tumor necrosis factor
alpha (TNF-) (161), its receptors (162, 163), and iNOS (164). Type I IFN- plays a much
more modest role in the control of infection of the type 2 ME49 strain in mice (165) and
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has also been shown to induce modest control in human macrophages (166). Type I
interferons may play a greater role in some strains that have been shown to drive very
high expression levels in vitro (167). Collectively, interferons likely lead to restricted
parasite growth through the induction of iNOS, an enhanced respiratory burst, restric-
tion of nutrients such as iron, and upregulation of speciﬁc pathways that target
intravacuolar pathogens (168). The potent activation of the Th1 responses can also be
detrimental to host survival, as shown in models of oral challenge with type 2 strains
(169) or during acute challenge with type 1 strains (170, 171), where enhanced levels
of proinﬂammatory cytokines result in pathology. Consistent with this, the induction of
a potent Th1 response is modulated by IL-10, the absence of which leads to greater
immunopathology (172). IL-27 also promotes regulatory T (Treg) cells that limit Th1
cell-mediated immunity in order to dampen inﬂammation (173).
Among the earliest and most strongly upregulated interferon-stimulated genes in
mice is a family of guanylate binding proteins (GBPs) called immunity-related GTPases
(IRGs) (174). The IRG family is expanded in mice, where it is important for the control
of T. gondii as well as other intracellular pathogens (175–177). Like other GTPases, IRGs
cycle between GDP-bound inactive and GTP-bound active forms (178). Normally, IRG
proteins are thought to remain sequestered to IrgM proteins, which act as stabilizers by
preventing GDP dissociation and thus preventing activation (179). Upon the recogni-
tion of a pathogen-containing vacuole, IRGs oligomerize and are recruited to the
vacuolar membrane, where they result in vesiculation and stripping of the vacuolar
membrane (180). The loss of the vacuole membrane results in the rapid killing of the
released tachyzoites (181). It is not certain how pathogen-containing vacuoles are
recognized, but several mechanisms have been suggested, including the absence of
self, due to a lack of IrgM proteins (182), or altered composition of membrane lipids
(183). A second group of immunity effectors that is also upregulated in response to
IFN- is the large GTPase family known as GBPs (184). GBPs are not recruited directly to
the PV but rather cluster in proximity to the PV membrane, where they occupy clusters
of membrane vesicles (185). Deletion of GBP1 (185), GBP2 (186), or a locus on chro-
mosome 3 (Chr3), which contains a cluster of six GBPs (187), compromises the control
of T. gondii in IFN--treated cells in vitro and increases the susceptibility of mice to
infection. Recent studies suggest that GBPs may be involved in this second step of
targeting to the parasite, directly leading to its destruction (188). Strains of T. gondii are
differentially susceptible to destruction by IRGs (189, 190) and GBPs (185, 191), and as
summarized below, this is due to active mechanisms of avoidance.
Autophagy contributes to innate immunity by capturing intracellular pathogens and
routing them for destruction by a process called xenophagy (192). In a somewhat
different role, the recruitment of IRGs and GBPs to the T. gondii-containing PV depends
on a core set of autophagy proteins, including Atg7, Atg5, Atg16, and Atg12, but not
the upstream activation steps or the degradation part of the pathway (180, 193, 194).
In the absence of these core Atg proteins, IRGs and GBPs form aggregates that are
spontaneously activated and cannot be recruited to the PV (185, 195). It has been
argued that this core group of Atg proteins is needed for homeostasis (185), such that
IRGs and GBPs are unstable in the absence of this pathway, similar to the loss of stability
in IrgM mutants (179). Alternatively, Atg proteins may be directly involved in the
recruitment of the IRG/GBP effectors to the PV membrane, as suggested by the early
delivery of LC3 to a portion of susceptible parasite-containing vacuoles (193). Regard-
less of the exact mechanism, the requirement for Atg proteins in the IFN- response
represents an intriguing link between innate immunity and cellular homeostasis path-
ways in host defense.
Innate Immunity in Humans
Humans are relatively resistant to infection despite the occasional occurrence of
disease, as described above. Human cells also rely on IFN- and STAT1 signaling to
control parasite replication in vitro (196). Although many of the ISGs regulated by IFN-
are similar in mouse and human, human cells control intracellular T. gondii by very
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different mechanisms than those described for mouse cells (197). First, humans lack
most IRGs and express only two forms, one of which is constitutively expressed in testis
(i.e., IRGC) and the other of which (i.e., IRGM) is truncated and likely does not function
in a manner analogous to that in mice (198). Second, although human cells express a
wide repertoire of GBPs (199), it has been questioned whether they participate in host
defense, as a clustered regularly interspersed short palindromic repeat (CRISPR) dele-
tion of the locus containing GBPs failed to show a role for these proteins in the control
of the intracellular replication of parasites in IFN--treated cells (194). However, other
reports suggest that some GBPs may contribute to the control of infection in some
human cells (200). Nonetheless, it appears that two of the main mechanisms of innate
resistance in IFN--stimulated mouse cells are not highly active in human cells. Addi-
tional mechanisms that have been described for IFN--treated human cells include the
increased production of reactive oxygen species (201), tryptophan limitation due to
the upregulation of indole amine oxidase (202), the sequestration of iron (203), and the
induction of the NALP1 inﬂammasome, leading to cell death and the loss of the
replicative niche (204). These mechanisms do not appear to act universally in all cell
types, and the disruption of any single pathway results in only a partial loss of IFN--
mediated control. These features suggest that each pathway may operate in parallel,
such that the control of parasite replication depends on their additive contributions.
Alternatively, these ﬁndings suggest that there are other important mechanisms that
operate in human cells.
Autophagy pathways have also been implicated in the control of T. gondii infec-
tion in human cells, and interestingly, the same core set of ATG5, ATG12, and ATG16
proteins is required. In IFN--treated HeLa cells, type 2 and 3 strain parasites are
susceptible to ubiquitination, the accumulation of the adaptors NDP52 and p62, and
the recruitment of LC3 (205), a canonical early marker for autophagosomes (206). Type
1 strain parasites avoid this ubiquitination-autophagy recruitment pathway by an
unknown mechanism (205). The accumulation of autophagy adaptors and LC3 leads to
engulfment of the PV in host membranes and restricted growth of type 2 parasites,
although the compartment does not fuse with lysosomes (205). Similarly to the mouse
system, this pathway requires pretreatment with IFN-, and the upstream activation
steps in the pathway (i.e., Beclin1 and Atg14) are not required (205). In addition to the
IFN--dependent ATG pathway that has been described for HeLa cells, a lysosome-
shunting mechanism that does not rely on ATG proteins has been described for human
umbilical vein endothelial cells (HUVECs) (207). Type 2 parasites are susceptible to this
IFN--induced pathway, which results in ubiquitination, p62 recruitment, and shunting
to lysosomes (207). Additionally, direct ligation of CD40 results in the recruitment of
LC3 to T. gondii-containing vacuoles, which are subsequently delivered to lysosomes in
a manner that is not IFN- dependent but relies on autophagy, including the upstream
activating steps (208, 209). The CD40 pathway is also important in mice, where it is
essential for the control of chronic infections in the central nervous system (210). It has
been argued that this pathway may be more important in humans, as genetic muta-
tions in STAT1 do not appear to render humans susceptible to toxoplasmosis, yet
mutations in CD154 (the CD40 receptor) cause X-linked hyper-IgM syndrome and result
in susceptibility to toxoplasmosis (211).
Deﬁning Pathogenesis Determinants
The mouse is a natural host, and as such, it provides an excellent model for under-
standing innate and adaptive immunity to T. gondii (212, 213). Moreover, differences in
strain-dependent phenotypes, combined with forward genetic analysis, have led to an
understanding of pathogenicity determinants that act by disrupting the host immune
system. These studies have taken advantage of the capacity for genetic crosses along
with linkage analysis (214) to identify genes that underlie phenotypes that differ among
the major strains types of T. gondii. This approach has been exploited to identify genes
that mediate acute virulence as well as augment immune signaling (197, 215).
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One of the most striking phenotypic differences among strains is their ability to
cause lethal infection with a low inoculum. Type 1 strains show a 100% lethal dose
(LD100) of a single organism in laboratory mice, independent of the mouse strain, while
those of type 2 show intermediate virulence, where LD50s can be deﬁned in outbred or
inbred mice, and the highly avirulent type 3 strains typically do not cause lethal
infection (68, 216). These differences were analyzed by using genetic crosses between
the type 1 GT-1 strain and the type 3 CTG strain, mapping a single quantitative trait
locus (QTL) on chromosome VIIa (217). Finer mapping of this locus and transcriptional
analysis of genes that were differentially expressed led to the identiﬁcation of ROP18,
a polymorphic secretory protein that encodes a serine/threonine kinase (217). ROP18 is
secreted from rhoptries during invasion, and it occupies small evacuoles that are
discharged into the host cytosol before becoming associated with the PV membrane
(217) (Fig. 1). The kinase activity as well as membrane anchorage are essential for the
virulence-enhancing properties of ROP18 (218). Parallel studies also identiﬁed ROP18 as
one of several QTLs that mediate differences between type 2 strain ME49 and type 3
strain CTG (219). Comparison of the expression proﬁles of ROP18 revealed that the
type 3 lineage underexpresses this protein by100-fold, and virulence can be restored
by overexpressing either the type 1 or the type 2 allele in the type 3 background (217,
219). Subsequent functional studies revealed that ROP18 targets the IRG family of
proteins, phosphorylating conserved threonine residues that lie in switch region 1 of
the GTPase domain (220, 221) (Fig. 1). Structural studies indicate that the hydroxyl
residues of these threonine residues interact with the phosphate groups of GTP (222).
Mutation of these residues to alanine prevents GTP hydrolysis and therefore blocks
oligomerization (221). By analogy, it is likely that the phosphorylation of these threo-
nine residues by ROP18 prevents GTP hydrolysis and oligomerization. In cells that
express ample levels of ROP18, IRGs fail to accumulate on the vacuole, and the parasite
survives, while a low level or absence of ROP18 leads to IRG recruitment and clearance
of the parasite. Hence, ROP18 can explain the resistance of type 1 parasites and the
susceptibility of type 3 strains to clearance by the IRG pathway.
Genetic mapping of a cross between the highly virulent type 1 GT-1 strain and the
intermediately virulent type 2 ME49 strain identiﬁed a new QTL on chromosome XII,
and subsequent ﬁne mapping revealed a cluster of repeated genes encoding a poly-
morphic pseudokinase, ROP5 (223). The ROP5 locus was also implicated in phenotypic
differences between type 2 and type 3 strains; in this case, the type 3 genotype was
associated with virulence enhancement, while that of type 2 was associated with
virulence suppression (224). From a genetic standpoint, the combination of alleles at
these two loci explains the high-virulence trait of type 1 (both ROP18 and ROP5 are
virulence enhancing), the intermediate phenotype of type 2 (ROP18 is virulence en-
hancing, while ROP5 is inhibitory), and the low virulence of type 3 (ROP18 is underex-
pressed, while a virulence-enhancing form of ROP5 is present but not sufﬁcient alone).
The identiﬁcation of the biochemical functions of ROP5 helped explain the basis for
these phenotypes (Fig. 1). ROP5 acts both to cooperatively enhance the kinase activity
of ROP18 (223) and to bind the substrate Irga6 (225), holding it in a conformation that
prevents assembly and that facilitates phosphorylation. Extension of these studies to
analyses of South American strains revealed that ROP18 is also highly expressed and
can rescue the normally nonvirulent type 3 lineage by complementation (226). Most
strains from South America have alleles at ROP18 and ROP5 that are related to the type
1 forms (227). A genetic cross between the type 10 VAND strain from South America
and the type 2 ME49 strain from North America conﬁrmed the role of ROP18 and ROP5
in acute virulence, and this was further extended by using CRISPR-Cas9 to delete these
genes from strains of several additional South American lineages (228).
Overexpression of ROP5 as a tandem afﬁnity-tagged protein in T. gondii conﬁrmed
that it binds to ROP18 in complex with several other pseudokinases and also led to the
identiﬁcation of a new active kinase called ROP17 (229) (Fig. 1). ROP17 is not highly
polymorphic, and hence, it was not mapped in any of the genetic crosses. However, a
deletion of ROP17 is synergistic with a loss of ROP18, and the double mutant pheno-
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copies the very strong defect of the Δrop5 mutant (229). ROP17 prefers to phosphor-
ylate IRG oligomers, accelerating their turnover in the process (229) (Fig. 1). ROP18 and
ROP17 have slightly different substrate preferences that are optimized for the two
different conserved threonine residues found in many IRG proteins (229). The ROP5-
ROP18-ROP17 complex(es) also contains other ROP pseudokinases of unknown func-
tion and a dense granule protein, GRA7, that also helps to disrupt IRG function (125)
(Fig. 1). GRA7 is a transmembrane protein that spans the PV and extends into the
cytosol, where it interacts with the ROP complexes (125). GRA7 also binds directly to
IRGs, and it accelerates their assembly and GTP hydrolysis in vitro (125). Collectively, this
complex of parasite secretory proteins targets the IRG system by accelerating turnover
(GRA7 and ROP17), binding to IRG monomers to prevent assembly (ROP5), and phos-
phorylating IRGs to prevent their assembly (ROP17 and ROP18) (Fig. 1). ROP18 and
ROP5 are also implicated in resistance to GBPs in mice (185), as is the pseudokinase
ROP45 (230). The level of complexity exhibited by this set of parasite effectors speaks
to the importance of thwarting the IRG and GBP host defense systems in mouse for
the survival of T. gondii. Furthermore, evidence that a large GTPase of this family can
overcome the ROP5 complex of normally virulent type 1 strains, leading to resistance
to infection in naturally resistant wild house mice (231), supports a model of coevolu-
tion of virulence factors and host defense mechanisms.
Despite the importance of the ROP5-ROP18-ROP17 complex(es) in thwarting innate
immunity in IFN--activated mouse macrophages, these effectors appear to play little
role in human cells (227). This difference likely reﬂects the fact that human cells express few
IRGs and that GBPsmay not play amajor role in IFN- resistance. Nonetheless, there is some
evidence that ROP18 alleles correlate with the severity of ocular disease in Colombia, and
the type 1 allele is associated with greater inﬂammation (232). ROP18 has also been shown
to target ATF6, a transcription factor that is part of the unfolded-protein response,
resulting in decreased antigen presentation by DCs to CD8 T cells in mice (233).
Hence, ROP18 may have other roles in adaptive immunity that are also relevant for
human toxoplasmosis.
TOXOPLASMA EFFECTORS THAT HIJACK HOST GENE EXPRESSION
From ROP Effectors to New Roles for GRA Proteins
Over the last decade, a wealth of studies has established that once intracellular, T.
gondii actively reprograms the gene expression of its host cell by subverting host cell
transcriptional machinery. To achieve this end, T. gondii has designed an arsenal of
molecular hijackers that take control of host cell gene expression. With this repertoire
of molecular weapons, it can target gene expression at both the transcriptional and
posttranscriptional levels by regulating the amount of mRNAs encoding proteins and
affecting noncoding RNAs, e.g., microRNAs, respectively (234, 235). An extra layer of
complexity comes with the speciﬁcity in the reshaping of gene transcription for given
host cell types and parasite strains. For instance, when macrophages and dendritic cells
are infected by the same T. gondii strain type, they undergo distinct programming,
while two different strain types trigger distinct transcript patterns in the same host cell
type (236).
Initial studies focused on differences in transcriptional responses following infection
of human or murine cells with different strain types. For instance, the use of gene
expression proﬁles to map the pathways that were differentially induced led to the
identiﬁcation of the secretory ROP kinase ROP16 that targets STAT3 and STAT6 (237)
(Fig. 1). The phosphorylation of STAT3 and STAT6 results in their activation and
transcription of a number of genes, including IL-4, polarizing the response to Th2 while
downregulating IL-12 production (237). Strain types 1 and 3 share a highly similar allele
of ROP16 that is highly active in phosphorylating STAT3 and STAT6, and the difference
in activity from the inactive type 2 allele was subsequently mapped to a single
polymorphic residue (238). T. gondii preferentially targets cell-speciﬁc transcription
factors that act as coordinating hubs in host defenses (i.e., NF-B, interferon regulatory
factor [IRF], and JAK/STAT) by regulating intrinsic activities and expression levels, which
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is often achieved through differential phosphorylation (239–242). Additionally, the
parasite can also drive changes in the host epigenetic landscape by co-opting
chromatin-modifying enzymes to selectively switch on/off gene transcription (160).
Identifying the parasite-derived molecular switches or effectors at play during the
reprogramming of gene transcription in infected cells and understanding further their
mode of action once delivered into the host cell cytoplasm are highly challenging
tasks. Rhoptry organelles known to release products concomitantly with cell invasion
were initially identiﬁed as the main source of such effectors (197). Hence, the recent
discovery of a still increasing repertoire of GRA proteins with host-modulating activities
expanded our understanding of host-pathogen interactions. Unlike ROP effectors that
are released in a burst during invasion (114), some GRA effectors are released in the
host cell over the entire period of T. gondii intracellular development. Below, we review
T. gondii GRA effector proteins that have convincingly been shown to contribute to the
building of functional networks in infected cells by interfacing with the host signaling
pathway or co-opting host transcription factors.
The Vacuole-Restricted GRA Effectors
The discovery of GRA15 and its extravacuolar activity deﬁned a new class of effectors
beyond the previous functions of GRA proteins that contribute to the biogenesis and
maturation of the PV and to nutrient acquisition (Fig. 2). Indeed, GRA15 from the type
2 background was shown to decorate the PV membrane following secretion and to
subsequently cause the activation and nuclear translocation of host p50/p65 NF-B
heterodimers, promoting the release of proinﬂammatory cytokines, including IL-12
(243). NF-B activation is dependent on TRAF6 and the IB kinase (IKK) complex but is not
dependent on MyD88 and TRIF (243). Type 1 strains drive an opposite pattern in that they
express a form of ROP16 that contributes to the suppressive effects of T. gondii infection
on lipopolysaccharide (LPS)-induced cytokine synthesis in macrophages (244) (Fig. 1).
Together, these two effectors determine the polarization of macrophages, with the type
1/3 form of ROP16 contributing to the induction of alternative activation, while the type
2 form of GRA15 drives classically activated macrophages (236). GRA15 has also been
implicated in inducing IL-1 production by human cells through the activation of
caspase 1 (245, 246).
The mechanism by which GRA15 from the type 2 background activates NF-B has
yet to be determined. The diversity of the NF-B family members, which in mammals
include ﬁve proteins, p65 (RelA), RelB, c-Rel, p105/p50 (NF-B1), and p100/52 (NF-B2),
that can further assemble into a combination of homodimeric and heterodimeric
species, provides high selectivity in the NF-B-mediated transcriptional response. De-
spite the fact that p65 and p50 translocate to the nucleus in a GRA15-dependent
manner (243), their relocation did not contribute to altering the levels of miR-146a and
miR-155, two NF-B-dependent microRNAs (234). On the other hand, miR-146a expres-
sion is impaired speciﬁcally in c-Rel/ mice (247). Additionally, c-Rel is activated upon
T. gondii infection but in a GRA15-independent fashion (234), thereby suggesting that
an effector(s) other than GRA15 could account for the activation of speciﬁc members of
the NF-B family, including c-Rel. The subversion of the NF-B pathway by T. gondii
remains to be clariﬁed, since type 1 strains were claimed to transiently block NF-B
nuclear translocation regardless of the host cell infected (248, 249), while type 2 strains
have opposite effects through the activity of GRA15 (243) and additional as-yet-
unidentiﬁed factors.
GRA6 is another secreted protein that displays a vacuole-restricted localization and
activates the host transcription factor NFAT4 (nuclear factor of activated T cells 4) in a
strain-speciﬁc manner, which promotes the synthesis of the chemokines Cxcl2 and Ccl2
(250) (Fig. 2). These chemokines attract inﬂammatory monocytes and neutrophils to the
infection site, where they control parasite spreading (250). NFAT activation requires a
conformational change that allows the exposure of the nuclear localization signal (NLS)
and subsequent NFAT nuclear translocation. Although the dephosphorylation of spe-
ciﬁc serine residues by calcineurin is responsible for this change, T. gondii GRA6 was
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shown to promote the activation of the phosphatase by a direct interaction with the
calcineurin activator calcium-modulating ligand (CAMLG) (250).
GRA16: Beyond the Vacuole Space
The PV membrane has been regarded as a sieve limiting the delivery of proteins
secreted by the parasite beyond the vacuolar space. However, the discovery of GRA16
and its remarkable ability to cross the PV membrane and to accumulate in the host cell
nucleus has changed this paradigm (Fig. 2). GRA16 was shown to trafﬁc to the host cell
nucleus together with a high-molecular-weight complex connecting the host phospha-
tase PP2A-B55 and the herpesvirus-associated ubiquitin-speciﬁc protease (HAUSP)
(251). Through its interactions with HAUSP, GRA16 provokes alterations in steady-state
protein levels of the tumor suppressor p53, while it induces the nuclear translocation
FIG 2 Secreted T. gondii effectors from dense granules transform host cell signaling pathways. After invasion of the host cell, T. gondii uses a large variety of
effector proteins originating from dense granule organelles to manipulate host signaling pathways and gene expression. Some of these proteins translocate
to the host nucleus (TgIST, GRA24, and GRA16), while others localize to the PV membrane (GRA15) or only partially interact with the host cell cytosol while
residing in the PV (GRA6). Present in all T. gondii type stains, the dense granule protein TgIST globally blocks the interferon (IFN) response by the recruitment
of the Mi-2/NuRD repressor complex to STAT1 binding sites in promoter regions of responsive genes. GRA24 bypasses the classical MAPK phosphorylation
cascades by forming a complex with p38, which is able to activate transcription factors such as EGR1 and c-Fos. GRA16 shuttles to the host nucleus while
bound to a high-molecular-weight complex, including PP2A-B55 and HAUSP, to control p53 levels. In type 2 strains, GRA15 activates the NF-B pathway by
the activation of TRAF6, which subsequently activates IKK, leading to the phosphorylation and degradation of IB. GRA6 has a vacuole-restricted location, and
its cytosolic region interacts with CAMLG to activate calcineurin and stimulate the transcription factor NFAT4.
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of the PP2A holoenzyme. GRA16 positively modulates the expression of host genes
involved in metabolism, cell cycle progression, and the p53 tumor suppressor pathway
(251).
The transcription factor p53 normally turns over rapidly, and it is maintained at low
levels in normal cells by Mdm2-mediated ubiquitination and proteolysis. The stabiliza-
tion of p53 in response to oncogene signaling is thought to result from deubiquitina-
tion by HAUSP. This pathway is also targeted by virus infection, as illustrated by the
Epstein-Barr virus protein EBNA1, which sequesters HAUSP from p53 and leads to its
degradation (252). GRA16 acts in an opposite manner by markedly increasing p53 levels
in a HAUSP-dependent manner (251). Other studies show that p53 is also an impor-
tant sensor of metabolic stress. For instance, upon glutamine deprivation, p53 is
activated to support cell survival in a B55a-dependent manner (253). It is probably not
a coincidence that GRA16 binds to PP2A-B55 and promotes its nuclear translocation,
nor is it a coincidence that glutaminase 2, a p53 target gene involved in glutamine
metabolism, is regulated by GRA16 in infected cells (251). Collectively, these results
support a role for GRA16 in promoting host cell survival under stress conditions by
simultaneously forming a complex with both HAUSP and PP2A-B55 to control p53
protein levels.
GRA24 and Molecular Mimicry
GRA24 shares with GRA16 the ability to reach the host nucleus and to regulate gene
expression (Fig. 2). GRA24 acts as a parasite-derived agonist that bypasses the classical
mitogen-activated protein kinase (MAPK) phosphorylation cascade and induces sus-
tained p38 autophosphorylation, forming a complex that is able to activate transcrip-
tion factors such as EGR1 or c-Fos (254). Therefore, GRA24 elicits a strong inﬂammatory
response by turning on the production of proinﬂammatory cytokines, in particular
CCL2/monocyte chemoattractant protein 1 (MCP-1) and IL-12, that enhance macro-
phage phagocytic activity at the site of infection and accordingly limit parasite burden
(254). GRA24 is an intrinsically disordered protein (IDP) that operates through two
atypical kinase-interacting motifs (KIMs), which combine attributes of docking domains
from multiple MAPK partners to maximize binding. GRA24 is capable of binding,
scaffolding, allosterically activating, and translocating p38 MAPK to the nucleus.
GRA24 interacts with two molecules of p38 via KIMs in its C terminus. The binding of
KIM1 to p38 alters the kinase domain conformation to activate the kinase. As shown
by small-angle X-ray scattering and atomic force microscopy, GRA24 scaffolds two
molecules of p38 in a ﬂexible manner but with enough proximity to enable autoac-
tivation via transphosphorylation (255). By adapting the KIM motif to bind to p38 in
a way that provides sustained activation while preventing the binding of regulatory
phosphatases (255), GRA24 is a prime example of how molecular mimicry contributes
to host-parasite relationships.
GRA24 was also found to trigger the activation of a gene network under the control
of the transcription factor CREB, but how it functions remains an open issue, since the
phosphorylation of CREB Ser133 correlated with T. gondii infection but was indepen-
dent of the GRA24/p38 pathway (254). CREB-Ser133 phosphorylation is involved in the
recruitment of the histone-modifying enzymes CBP (CREB binding protein) and its
paralog p300, which in turn were shown to facilitate transcription by catalyzing histone
acetylation (256). Because GRA24 copuriﬁed with both CBP and p300 (M.-A. Hakimi,
unpublished data), it is plausible that GRA24 shortcuts the phospho-CREB activation
step and operates directly to remodel the chromatin structure in the vicinity of
CREB-regulated genes.
TgIST Modiﬁes Host Chromatin and Acts as an Epigenator
As detailed above, the cytokine IFN- acts at the frontline of defense against T.
gondii. Early studies proposed that T. gondii counters this defense by remodeling the
host cell to be unresponsive to IFN- at the transcriptional level in both humans and
mice (240). Next, it was convincingly argued that T. gondii infection inhibits STAT1
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transcriptional activity by blocking nuclear-cytoplasmic cycling (241). Only recently has
the missing link between the two layers been elucidated with the discovery of another
protein stored in dense granule-like organelles, which was identiﬁed as T. gondii
inhibitor of STAT transcription (TgIST), based on its negative regulatory activity on the
IFN--dependent signaling pathway (257, 258) (Fig. 2). This pathway starts when a
signal is transduced through the IFN- receptor and successively leads to the phos-
phorylation of STAT1 on the Y701 residue (Y701-P), the dimerization of STAT1, and its
nuclear translocation. Nuclear STAT1 then regulates gene expression by binding to
gamma-activated sequence (GAS) elements in the promoters of genes that respond to
IFN- (e.g., IRF1). The transcriptional activity of STAT1 increases with a second independent
phosphorylation event on S727. The dual Y701-S727 phosphorylation of STAT1 that typiﬁes
the chromatin-bound pool of STAT1 (259) promotes chromatin opening through a part-
nership with enzymes such as histone acetyltransferase (HAT) and p300/CBP, which to-
gether stimulate gene expression (260).
In cells infected by T. gondii, TgIST translocates across the parasitophorous vacuole
and accumulates in the host cell nucleus, where it binds ﬁrmly to both activated STAT1
Y701-P and chromatin-modifying proteins found in the nucleosome-remodeling and
deacetylase (NuRD) complex (257, 258) (Fig. 2). This complex contains the chromatin-
remodeling ATPase (CHD3 and CHD4) and deacetylation (histone deacetylase 1
[HDAC1] and HDAC2) enzymes and the transcriptional corepressors C-terminal binding
protein 1 (CtBP1) and CtBP2 (257, 258). In the context of Stat1-deﬁcient U3A cells, the
association of TgIST with NuRD and CtBPs was shown to be STAT1 independent,
suggesting that TgIST bears distinct domains for binding to NuRD/CtBP and STAT1.
Moreover, on the basis of assays using IRF1 mRNA and protein levels to monitor
STAT1-mediated transcription, TgIST is the primary parasite protein responsible for
inhibiting the STAT1-dependent responsiveness of the host cell to IFN- (257, 258).
Upon IFN- stimulation, STAT1 nuclear relocation occurs normally, but this host tran-
scription factor remains silent due to its sequestration with the NuRD complex by TgIST.
Intriguingly, TgIST promotes STAT1 Y701 phosphorylation and nuclear translocation
in the absence of IFN- treatment (257, 258). The ectopic expression of TgIST was
sufﬁcient to trigger this unusual IFN--independent STAT1 Y701 phosphorylation, most
likely through the recruitment of host kinases qualiﬁed to shortcut the JAK/STAT
pathway by TgIST (257). Of note, in the absence of IFN- stimulation, T. gondii infection
still drives the phosphorylation of S727 and subsequent STAT1 nuclear translocation in
a TgIST-dependent fashion (257), suggesting that a chromatin-bound pool of STAT1
could be present in the vicinity of IFN--inducible genes. Chromatin immunoprecipitation-
quantitative PCR (ChIP-qPCR) analysis provided such evidence, since dual Y701-S727
phosphorylation of STAT1 was found to be markedly enriched at GAS-containing
promoters under these conditions (257).
Despite detailed studies demonstrating that TgIST mediates the transcriptional
repression of IFN--inducible genes, the precise molecular mechanism for this altera-
tion remains uncertain. HDAC enzymes embedded in the NuRD complex to which TgIST
binds were ﬁrst thought to be involved, but HDAC inhibitors targeting both class I and
II enzymes were inefﬁcient at preventing TgIST from inhibiting the IFN--induced
expression of IRF1 (257), as previously reported (241). Meanwhile, histone modiﬁcation
proﬁling led to discordant results, pointing to the need to investigate TgIST properties
further. Indeed, while Gay et al. (257) reported that TgIST was not involved in modu-
lating the acetylation state of histones, Olias et al. (258) found that T. gondii infection
signiﬁcantly reduced the acetylation status of histone H3 at HLA-E and GBP1 loci in a
TgIST-dependent fashion. An alternative hypothesis would be that TgIST-bound HDACs
compete with HAT to prevent STAT1 acetylation and DNA dissociation, thereby com-
promising STAT1 recycling, in line with a model proposed by Krämer and Heinzel (261).
Assuming that HDACs might not be involved, the NuRD-associated ATP-dependent
chromatin-remodeling enzymes CHD3 and CHD4 could play a critical role in TgIST-
mediated transcriptional repression by inﬂuencing nucleosome positioning to create a
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nonpermissive chromatin state (262). Further studies will be required to unravel these
complexities.
Further proﬁling of histone modiﬁcations in T. gondii-infected cells revealed that
H3K4me3, a hallmark of activation, was sustainably enriched at repressed STAT1
binding loci in a TgIST-dependent fashion and regardless of IFN- stimulation (257).
Remarkably, this paradox mirrors those of stem cells that are typiﬁed by a repressive
H3K27me3 (histone 3, lysine 27, trimethyl mark) combined with an activating H3K4me3
(histone 3, lysine 4, trimethyl mark) that provides a bimodal signature to silence
developmental genes while keeping them poised for rapid activation (263, 264). If the
analogy is pushed further, TgIST could be considered an epigenator, according to the
deﬁnition of Berger et al. (265), suggesting that it acts as a repressive “memory mark.”
At the cellular level, TgIST plays its major role early during infection by protecting
the ﬁrst wave of invading tachyzoites within naive cells by blocking potent ISG-
mediated parasite killing (257, 258). However, this STAT1 silencing mechanism loses
efﬁciency when myeloid cells are already primed by previous exposure to IFN- (258).
This time-restricted activity of TgIST is consistent with the control of parasite expansion,
although not complete clearance, as shown when mice were infected with TgIST-
deﬁcient T. gondii (257, 258). Hence, while TgIST can protect parasites within naive cells,
there are other STAT1-dependent pathways that overcome this block and that are
required to control toxoplasmosis (152, 156, 266).
Patterns That Emerge from GRA Effectors
Although there are as yet only a few GRA effectors characterized, we can make some
general conclusions about their modes of action. First, there are two classes of effectors,
those acting locally, near their secretion site (i.e., GRA6 and GRA15), and those acting
at a longer distance, with the host nucleus as a ﬁnal destination (i.e., GRA16, GRA24, and
TgIST). Second, although the former effectors seem to interfere indirectly with their
dedicated pathways, the latter ones seem to form hyperstable interactions with host
proteins and to reshufﬂe the host interactome by gathering together enzymes/proteins
that are usually not associated in uninfected cells. For instance, there is no precedent
for any interaction of the NuRD complex with STAT transcription factors. Finally,
different proteins can operate in effector communities by the convergent targeting of
a common host cell pathway, for instance, M1 activation by GRA15 (243) and GRA24
(254). These effectors may adopt at least three alternative, although not mutually
exclusive, strategies to subvert host gene expression. They may (i) modulate upstream
signaling pathways (i.e., GRA6 and GRA24), (ii) directly target host transcription factor
protein levels/activity (i.e., GRA15, GRA16, and TgIST), and/or (iii) affect histone
packing and chromatin conﬁguration (i.e., GRA24 and TgIST). However, and unlike
the transcription activator-like (TAL) proteins secreted by phytopathogenic Xan-
thomonas and Ralstonia species (267), none of the T. gondii nucleus-targeted
proteins described so far were able to mimic eukaryotic transcription factors and to
bind directly to host cell DNA.
PROTEIN TRAFFIC WITHIN AND BEYOND THE VACUOLE
Protein Order and Function: Disordered To Conquer
The high abundance of intrinsically disordered regions (IDRs) combined with short
linear motifs (SLIMs) in dense granule-derived effectors strongly suggests positive
evolutionary selection of these structural features (268). The secretion of IDR proteins
across membranes does not require active unfolding and thus would be advantageous.
Additionally, structural ﬂexibility may have other advantages beyond the ease of
secretion and trafﬁcking. In the context of the coevolutionary arms race between host
and pathogen, the evolutionary time scales of the IDR are shorter than those required
for globular domains (e.g., DNA binding domains) (269–272). IDR proteins exhibit
higher rates of point mutations and repeat expansions than do folded proteins, and
these properties could facilitate the evasion of immune recognition. Part of the effector
strain speciﬁcity could stem from the evolution of their internal SLIM. For instance,
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C-terminal polymorphisms on GRA6 control strain-speciﬁc NFAT4 activation (250).
Furthermore, IDR proteins are able to accommodate multiple protein partners and
thereby maximize functional complexity with a reduced parasite “effectome.” While
mimicking host cell proteins, parasite effectors can gain efﬁcacy over their native
counterparts at modifying host cell signaling pathways, as demonstrated by GRA24
(255). Studies of these dynamic regions and their quick evolution to optimize their
function inside host cells as a pathogenic scaffold/hub may help predict new parasite
effectors that are yet to be identiﬁed. We have attempted to highlight a few
examples that illustrate how some degree of disorder is required for parasite effectors
to perform their prescribed functions in the infected cell, and this feature may also
inﬂuence their trafﬁcking. Such features are not restricted to parasites, as IDR proteins
are quite common in eukaryotic proteomes. For instance, IDR proteins are frequently
observed in nucleic acid binding proteins and in the proteins that interact with them
(273). Going forward, studies of these IDR proteins will aid in gaining general insight
into how a protein’s ﬂexibility enables its function.
Comparisons to Plasmodium Export
Communication between the parasite and the host cell takes place across the PV
membrane, which is porous to small molecules (136) but resistant to fusion with
endomembranes of the host (168) (Fig. 3). The current molecular understanding of
export beyond the PV is fueled mainly by Plasmodium studies, which revealed that
exported proteins trafﬁc through the secretory pathway and are exported to the
FIG 3 Mechanisms of protein export and trafﬁc beyond the PV. The aspartyl protease ASP5 is situated at the Golgi apparatus
of the parasite. The cleavage of some (i.e., GRA15, GRA16, and TgIST) but not all (i.e., GRA24) dense granule proteins in their
recognition signal by ASP5 is necessary for the export of these proteins. MYR1 is part of a protein complex located at the PV
membrane, where it is involved in the export of intrinsically disordered dense granule proteins across the vacuole membrane
and into the host cytosol. A number of these export substrates are processed by ASP5. Two additional dense granule proteins,
GRA17 and GRA23, which are also located at the PV membrane, are responsible for small-molecule transport between the host
cytosol and the vacuole lumen.
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vacuolar lumen before crossing the PV membrane (reviewed in reference 274). The
majority of these proteins are typiﬁed by a signal peptide for ER entry followed by a
conserved sequence motif (RxLxE/Q/D), referred to as the host targeting (HT) motif or
the Plasmodium export element (PEXEL), which is required for export across the PV
membrane into the host cell. The HT/PEXEL motif is recognized by a wide repertoire of
known Plasmodium proteins by the ER-resident aspartyl protease plasmepsin V (PMV),
which cleaves after the leucine, followed by N-terminal acetylation (reviewed in refer-
ence 274). Once posttranslationally modiﬁed, these proteins have all the attributes to
be targeted by a parasite translocon located at the PV membrane, named Plasmodium
translocon of exported proteins (PTEX). Although the PV membrane represents a barrier
that exported proteins must cross before entering the host cytoplasm, protein unfold-
ing is also necessary for HT/PEXEL proteins to cross the vacuolar membrane before
being refolded and trafﬁcked to their ﬁnal destination, implicating an ATP-powered
step in export (reviewed in reference 274). In line with these requirements, the PTEX
complex was described as a multiple-protein complex, including a chaperone, HSP101,
which facilitates the translocation process; thioredoxin 2, which reduces disulﬁde
bonds; and a single-membrane protein named EXP2, which is predicted to form a
protein-conducting channel (reviewed in reference 274).
Trafﬁcking of GRA Proteins in T. gondii
Initially, the export mechanism was thought to be phylogenetically conserved across
the phylum. Nonetheless, while the translocon that mediates the transport of proteins
across the PV membrane remains enigmatic, the recent discovery of exported GRA
proteins offers new insights into trafﬁcking through the PV membrane in T. gondii. An
early study identiﬁed sorting signal sequences reminiscent of the HT/PEXEL motif in the
T. gondii GRA19, GRA20, and GRA21 proteins (275). However, while their motifs were
proteolytically processed, they do not cross the PV membrane and are instead relo-
cated to the PV membrane (276). Meanwhile, GRA16 and GRA24 offer more suitable
molecular markers to monitor protein export and to evaluate whether the export
machinery is similar to the Plasmodium system.
The role of ASP5, the T. gondii homolog of Plasmodium plasmepsin V, has recently
been assessed (Fig. 3). In the absence of ASP5, the T. gondii proteins GRA19 and GRA20
fail to localize to the PV membrane. Notably, in Δasp5mutants, GRA16 and GRA24 were
no longer exported in the host cell nucleus but were retained in the vacuolar space
(276–278). The HT/PEXEL-like motifs of GRA16, GRA19, and GRA20 were shown to be
directly processed by ASP5 (276–278). Unexpectedly, GRA24, which does not have a
conserved HT/PEXEL motif, was processed in an ASP5-independent fashion, although
ASP5 was required for its export (278). An alternative pathway for the export of the
HT/PEXEL-negative exported proteins (PNEPs), which involves a different protease(s)
than PMV, has been described in Plasmodium (reviewed in reference 274) and may also
exist in T. gondii. The export of TgIST required maturation by ASP5; however, whether
its predicted HT/PEXEL motif corresponds to a direct cleavage site for ASP5 remains to
be determined (257).
Unlike Plasmodium PMV, ASP5 is not essential, but its deletion triggers a decrease of
parasite ﬁtness and multiple phenotypes, including the loss of the intravacuolar
network, and impairment of host mitochondrial recruitment at the PVM (276, 277). As
expected, asp5-deﬁcient parasites showed a greatly diminished ability to modulate host
cell gene expression and were more susceptible to immune responses during infection
(276, 277). As predicted by their pleiotropic phenotypes, asp5-deﬁcient parasites were
severely attenuated in a murine model of infection (276, 277).
The HT/PEXEL motif does not sufﬁciently typify the T. gondii exported GRA proteins
identiﬁed so far. However, structural analysis revealed that, unlike ROP proteins, they
are predicted to be devoid of a known catalytic domain (e.g., kinase domain) and are
natively unfolded (268), as illustrated by GRA24 (255). Their intrinsically disordered
nature (i.e., the lack of a stable tertiary structure) would be of an inherent advantage for
PV membrane crossing, as it would not require active unfolding. Support for this
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hypothesis was provided by the observation that epitope tagging of either GRA16 or
GRA24 with ﬂuorescent proteins (mCherry or green ﬂuorescent protein [GFP]) inhibited
PV membrane crossing, yet similar reporter proteins are routinely used in Plasmodium
studies. In agreement with these data, it was shown that applying structural constraints
to GRA16, for example, by fusing any folded protein fragments (e.g., dihydrofolate
reductase [DHFR]) to the protein, led to an impairment of its export outside the PV
membrane (278). Conversely, the addition of a disordered protein fragment to GRA16
did not alter the trafﬁcking of the protein to its ﬁnal destination (278). More impor-
tantly, the size of the polypeptide does not limit progression through the membrane,
as illustrated by GRA28, a disordered and high-molecular-mass (200-kDa) protein that
crosses the PVM to accumulate in the host cell nucleus (279). These data contrast
deeply with those for Plasmodium showing that protein unfolding is necessary during
the export of proteins bearing PEXEL and PNEP motifs and that HSP101 provides the
power source for unfolding (reviewed in reference 274). Thus, T. gondii has indepen-
dently evolved an elementary export machinery that preferentially accommodates
disordered proteins as a way to save energy and most likely to evolve SLIM-mediated
interactions with the host cell.
Transport Complexes in the PV Membrane
If protein folding is not a limiting factor for export, the question of the existence of
a protein-conducting channel remains. Plasmodium EXP2 was suspected to oligomerize
and to form a pore based on similarity to Escherichia coli hemolysin E in modeling
studies. Phylogenetic analysis revealed that T. gondii encodes two proteins with ho-
mology to EXP2, namely, GRA17 and GRA23, both of which localize to the PV mem-
brane and, when expressed in Xenopus laevis oocysts, can form a large membrane pore
similarly to hemolysin (280) (Fig. 3). Their deletion in T. gondii resulted in abnormal
morphology with swelling of the PV (280). This phenotype was explained by their ability
to mediate the transport of small molecules (3,000 Da) but not protein export across
the PV membrane, as neither Δgra17 nor Δgra23 mutants altered the export of GRA16
or GRA24 to the host cell (280). Interestingly, Plasmodium EXP2 functionally fully
complements solute transport that is reduced in a T. gondii gra17-deﬁcient mutant,
raising the possibility that EXP2 may play a dual role as a nutrient pore and a protein
channel (280).
The Plasmodium model of protein translocation through the PV membrane is
evidently challenged by insights from T. gondii, whether it concerns the requirement of
a PEXEL addressing signal, ATP-powered unfolding, or an EXP2-forming pore for a T.
gondii GRA protein to cross the PV membrane. Therefore, simple comparative analogies
may not readily reveal the diversity of protein export mechanisms present in this
phylum. In this regard, a genetic screen originally set up to identify the effector protein
responsible for c-Myc induction by T. gondii led to the identiﬁcation of MYR1 and an
alternative translocation pathway (281) (Fig. 3). MYR1 is processed by ASP5 into two
stable portions (277), both of which are located in the PV and associate with the PV
membrane (281). The export of GRA16, GRA24, and TgIST was impaired in cells infected
by myr1-deﬁcient parasites, while MAF1 and GRA15 functions were not altered, sug-
gesting that MYR1-dependent export is devoted only to dense granule proteins that
physically translocate across the PV membrane and accumulate in host cell compart-
ments (281). This is a major difference from ASP5, which embraces a wider repertoire
of GRA proteins. Phylogenetic analysis revealed that no convincing homolog of MYR1
was detectable in Sarcocystis, a coccidian that lacks a PV but instead develops in the
host cell cytoplasm, or in the more distantly related genera Eimeria and Plasmodium,
suggesting that the MYR1 pathway is speciﬁc to a subset of tissue cyst-forming
coccidia.
ADDITIONAL PATHWAYS ALTERED BY T. GONDII INFECTION
In addition to the examples cited above, there are several host transcription factors
whose activities are regulated by T. gondii infection but for which no effectors have yet
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been identiﬁed. Infection by T. gondii activates hypoxia-inducible factor (HIF), and this
pathway is important for the optimal growth of the parasite under hypoxic conditions
(282). Although upstream regulators of this pathway have been identiﬁed, including
activin-like receptor kinase (283), the parasite mediator that triggers this pathway
remains uncharacterized. Additionally, T. gondii induces the phosphorylation of CREB-
Ser133 and ATF2-Thr71, and this occurs independently of GRA24 (254). The parasite
also promotes the induction of c-Myc, an unknown effector that relies on MYR1 for
export (281), and EGR2 (284), and these responses are downstream of the serum
response factor, which is triggered by T. gondii infection (242). Infection is also
associated with the noncanonical activation of mTOR and the phosphorylation of the
ribosomal protein S6 (285).
Host cells are equipped with several pathways for inducing cell death, including
apoptosis and pyroptosis, and these pathways often function in host defense. Infection
by T. gondii blocks both intrinsic (i.e., cytotoxic stress and DNA damage) and extrinsic
(i.e., death receptor activation) pathways triggering apoptosis (286–292). Although the
ability to block cell death may be important for ensuring a stable intracellular niche, the
effectors that disrupt this pathway have not been identiﬁed. Infection by T. gondii has
also been described to activate inﬂammasome activation in murine (245), rat (293), and
human (204) cells. Although GRA15 from type 2 strains contributes to this pathway by
activating NF-B and inducing IL-1 induction in human cells (246), the second signal
that directs inﬂammasome activation remains uncharacterized. Inﬂammasome activa-
tion likely plays a role in host defense, as the resulting cell death limits the replicative
niche for parasite survival, making this an attractive pathway for the parasite to
manipulate.
As mentioned above, components of the autophagy pathway are involved in
regulating innate resistance to T. gondii in mouse and human cells. Although the role
for ATG proteins in murine cells can be accounted for by IRGs (180, 193) and GBPs
(185–187), these effectors are unlikely to play a role in human cells (194). Thus, the
strain-dependent avoidance of ATG-mediated control by type 1 strains is likely due to
a strain-speciﬁc mediator that blocks either this pathway or a susceptibility factor that
allows the restriction of type 2 and 3 strains (205, 207). The role of ATG proteins in
innate immunity is dependent on prior activation with IFN-. Under nonstimulated
conditions, infection has been associated with the induction of host cell autophagy
leading to enhanced parasite growth, although the mechanism by which this is
triggered remains unknown (294).
CONCLUSIONS AND FUTURE DIRECTIONS
Although the last decade has seen signiﬁcant progress in identifying parasite
effectors, there are many ROP and GRA effectors for which the cellular targets and
biological signiﬁcance remain unknown. For example, there are more than 20 active
ROP kinases and an equal number of pseudokinases (295), yet we know of functions for
only a few of them (197). Similarly, there are a large number of GRA proteins for which
functions have not been assigned, including the vacuolar protein GRA25, which inﬂu-
ences immune responses in mice (296), and the host nucleus-targeted GRA28 protein
(279). The diversity of these effectors may reﬂect the large number of different hosts
infected by T. gondii, and the functions of other effectors may be revealed by studying
a broader range of hosts.
Additionally, where effectors have been identiﬁed, they may not act alone. For
example, while studying GRA16, we noticed that while GRA16 modulates p53 protein
levels, paradoxically, the levels of the cell cycle inhibitor p21cip1/waf, a direct p53
downstream target, were not fully regulated by GRA16 (251), suggesting that another
effector(s) may be involved in this pathway. A similar conclusion was drawn while
investigating the activation of miR-146a and miR-155 by parasite infection: despite the
fact that these microRNAs are regulated by NF-B, they were not controlled by GRA15,
a known activator of this transcription factor (234). Hence, T. gondii effectors may
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inform us about the regulation and interaction of intrinsic cellular signaling pathways
by serving as probes to dissect their functions.
Our understanding of protein export pathways has recently expanded with the
recognition that ASP5 plays a role in T. gondii (276–278) parallel to that previously
discovered in Plasmodium (reviewed in reference 274). Also, there are clearly novel
activities on the PV, including the MYR1 complex involved in protein export (281) and
the GRA17/23 complex implicated in import (280). The currently described components
do not seem sufﬁciently complex to be solely responsible for such intricate activities,
and it is likely that additional components of these systems will be discovered. Among
the as-yet-unanswered questions are “What mechanism is involved in the recognition
of proteins for export beyond the PV?” and “Does this depend primarily on their
intrinsically disordered structure, or are there escort proteins that shuttle cargo through
this pathway?” Additionally, it is possible that some components of the GRA17/23
complex implicated in nutrient import may also participate in protein export.
Although most effectors that target host transcription do this by altering proteins
that then interact with transcription factors, TgIST acts in a novel way to alter host
chromatin (257, 258). The TgIST-mediated alterations that are seen in the host epig-
enome raise the question of whether T. gondii effectors are able to promote “epigenetic
memory” in resident cells at the site of infection that lasts far beyond the immunolog-
ical clearance of the infecting pathogen. It also raises the possibility that there are other
effectors that act to modify chromatin marks on host genes, thereby affecting gene
expression, a theme that is common among bacterial pathogens but as yet largely
unexplored in eukaryotic pathogens (297).
With the rapid identiﬁcation of effectors in T. gondii, it seems surprising that they
remained anonymous for as long as they did. The delay in recognizing effectors might
be attributed to the fact that the genes and the proteins that they encode are highly
divergent, which is itself a clue that they are under strong selective pressure to evolve.
The advent of unbiased genetic systems led to the discovery and validation of secretory
effectors in T. gondii. However, neither the pathways disrupted by T. gondii nor all the
effectors identiﬁed are conserved in closely related parasites such as Hammondia or
Neospora. This pattern may underlie the broader host range of T. gondii, perhaps due
to a greater range of effectors that target the host, or may simply reﬂect the diversity
of adaptation among different parasites. Regardless of the degree of conservation
versus novelty, the value in deﬁning these pathways may be in modulating the ability
of the parasite to disrupt host pathways, thereby augmenting immune responses and
perhaps dampening immune pathology.
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